Are you over 18 and want to see adult content?
More Annotations
![A complete backup of https://edenly.com](https://www.archivebay.com/archive6/images/5521b6e5-9ae3-4a65-8a13-5712dd35993d.png)
A complete backup of https://edenly.com
Are you over 18 and want to see adult content?
![A complete backup of https://tapiola.fi](https://www.archivebay.com/archive6/images/8821a490-56fc-47f4-a073-d19fad06d863.png)
A complete backup of https://tapiola.fi
Are you over 18 and want to see adult content?
![A complete backup of https://avionews.com](https://www.archivebay.com/archive6/images/1f5b2578-408e-4695-adbe-505717ae2b05.png)
A complete backup of https://avionews.com
Are you over 18 and want to see adult content?
![A complete backup of https://uwcu.org](https://www.archivebay.com/archive6/images/99bd57c9-089e-4e6d-b12e-9743d3cc7b16.png)
A complete backup of https://uwcu.org
Are you over 18 and want to see adult content?
![A complete backup of https://nationalgallery.ie](https://www.archivebay.com/archive6/images/57516ceb-c586-46a2-8a85-eb8859b001f6.png)
A complete backup of https://nationalgallery.ie
Are you over 18 and want to see adult content?
![A complete backup of https://editions-memo.fr](https://www.archivebay.com/archive6/images/fa7736bc-c45b-456e-a0f4-39e00f39b606.png)
A complete backup of https://editions-memo.fr
Are you over 18 and want to see adult content?
![A complete backup of https://comfortkeepers.com](https://www.archivebay.com/archive6/images/5fede0cd-81e6-4971-8843-3e31bd44989a.png)
A complete backup of https://comfortkeepers.com
Are you over 18 and want to see adult content?
![A complete backup of https://la-gruyere.ch](https://www.archivebay.com/archive6/images/40a3abeb-73f3-4b8f-b2bf-3435a77311b1.png)
A complete backup of https://la-gruyere.ch
Are you over 18 and want to see adult content?
![A complete backup of https://burberryoutletsale.com.co](https://www.archivebay.com/archive6/images/cd3df997-697d-41ba-b7de-8b454ac3842d.png)
A complete backup of https://burberryoutletsale.com.co
Are you over 18 and want to see adult content?
![A complete backup of https://middleeastdirectory.com](https://www.archivebay.com/archive6/images/d0cc1e55-2ab6-4960-974e-e3ad0d2475bf.png)
A complete backup of https://middleeastdirectory.com
Are you over 18 and want to see adult content?
![A complete backup of https://richardandkarencarpenter.com](https://www.archivebay.com/archive6/images/8bee62da-5846-4199-b50c-1878b8e2a5c2.png)
A complete backup of https://richardandkarencarpenter.com
Are you over 18 and want to see adult content?
![A complete backup of https://fundacioncaser.org](https://www.archivebay.com/archive6/images/1924e3f1-1584-4add-9f5e-9305de39bb73.png)
A complete backup of https://fundacioncaser.org
Are you over 18 and want to see adult content?
Favourite Annotations
![A complete backup of myclientsplus.com](https://www.archivebay.com/archive2/54b9529c-895e-4bf3-9539-83e2c70dc8ba.png)
A complete backup of myclientsplus.com
Are you over 18 and want to see adult content?
![A complete backup of presidiogolf.com](https://www.archivebay.com/archive2/012f9d46-8f7d-4847-a60e-d09be933da51.png)
A complete backup of presidiogolf.com
Are you over 18 and want to see adult content?
![A complete backup of churchmissionsociety.org](https://www.archivebay.com/archive2/ac0cdbcc-62a4-4815-973c-b302f2441bcb.png)
A complete backup of churchmissionsociety.org
Are you over 18 and want to see adult content?
![A complete backup of utelementary.org](https://www.archivebay.com/archive2/509a9cfa-1867-46f0-aefe-e159d63a86fd.png)
A complete backup of utelementary.org
Are you over 18 and want to see adult content?
Text
COVID-19 PROGRAMS
COVID-19 VaccineDevelopment Program. On March 12, 2020, Medicago announced the successful production of Virus-Like Particle (VLPs) of the coronavirus just 20 days after obtaining the SARS-CoV-2 (virus causing the COVID-19 disease) gene. Production of VLPs is the first step in developing a vaccine against COVID-19 before preclinicaltesting for
ABOUT MEDICAGO
Doing things differently since 1999. The story of Medicago is rooted in a long track record of innovation and perseverance. Even our company name – the Latin word for alfalfa, which was the first plant we worked with – embodies our culture of adaptation. We're proud of our humble beginnings as much as we are of our current growth andglobal
MEDICAGO ANNOUNCES POSITIVE PHASE 1 RESULTS FOR ITS COVID Medicago announces positive Phase 1 results for its COVID-19 vaccine candidate. 100 per cent of subjects who received an adjuvanted vaccine candidate developed significant antibody and cellular immune responses after two doses. QUEBEC CITY, November 10th, 2020 - Medicago, a biopharmaceutical company headquartered in Quebec City, is pleased to CAREERS OPPORTUNITIES IN QUEBEC CITY One of the most attractive opportunities Medicago offers our employees is the chance to contribute to game-changing technology and innovative products. Within the biotechnology and pharmaceutical sectors, it can be challenging to get hands-on experience in projects beyond yourday-to-day role.
DEVELOPING NOVEL VACCINES AND THERAPEUTIC PROTEINS Medicago is a leading clinical-stage biopharmaceutical company using disruptive plant-based and virus-like particle (VLP) technologies to rapidly develop innovative vaccines and protein-based therapeutics for infectious diseases and emerging public health challenges. MEDICAGO AND GSK START PHASE 3 TRIAL OF ADJUVANTED COVID Medicago and GSK start Phase 3 trial of adjuvanted COVID-19 vaccine candidate. QUEBEC CITY, LONDON, March 16th, 2021 - Medicago, a biopharmaceutical company headquartered in Quebec City and GlaxoSmithKline (GSK), are pleased to announce the start of Phase 3 clinical testing of Medicago's plant-derived COVID-19 vaccine candidate in combinationCOVID-19 PROGRAMS
COVID-19 VaccineDevelopment Program. On March 12, 2020, Medicago announced the successful production of Virus-Like Particle (VLPs) of the coronavirus just 20 days after obtaining the SARS-CoV-2 (virus causing the COVID-19 disease) gene. Production of VLPs is the first step in developing a vaccine against COVID-19 before preclinicaltesting for
ABOUT MEDICAGO
Doing things differently since 1999. The story of Medicago is rooted in a long track record of innovation and perseverance. Even our company name – the Latin word for alfalfa, which was the first plant we worked with – embodies our culture of adaptation. We're proud of our humble beginnings as much as we are of our current growth andglobal
MEDICAGO ANNOUNCES POSITIVE PHASE 1 RESULTS FOR ITS COVID Medicago announces positive Phase 1 results for its COVID-19 vaccine candidate. 100 per cent of subjects who received an adjuvanted vaccine candidate developed significant antibody and cellular immune responses after two doses. QUEBEC CITY, November 10th, 2020 - Medicago, a biopharmaceutical company headquartered in Quebec City, is pleased to CAREERS OPPORTUNITIES IN QUEBEC CITY One of the most attractive opportunities Medicago offers our employees is the chance to contribute to game-changing technology and innovative products. Within the biotechnology and pharmaceutical sectors, it can be challenging to get hands-on experience in projects beyond yourday-to-day role.
MEDICAGO ANNOUNCES POSITIVE PHASE 1 RESULTS FOR ITS COVID Medicago announces positive Phase 1 results for its COVID-19 vaccine candidate. 100 per cent of subjects who received an adjuvanted vaccine candidate developed significant antibody and cellular immune responses after two doses. QUEBEC CITY, November 10th, 2020 - Medicago, a biopharmaceutical company headquartered in Quebec City, is pleased to MEDICAGO ANNOUNCES PRODUCTION OF A VIABLE VACCINE Medicago announces production of a viable vaccine candidate for COVID-19. March 12, 2020. Press Release. The biopharma successfully produced Virus-Like Particles (VLP) of the coronavirus in just 20 days using proprietary plant-based technology. Medicago's platform can produce both vaccine and antibody candidates against COVID-19 disease. MEDICAGO BEGINS PHASE I CLINICAL TRIALS FOR ITS COVID-19 First doses administered to human volunteers. QUEBEC CITY, July 14, 2020 - Medicago, a biopharmaceutical company headquartered in Quebec City, began Phase I clinical trials for its plant-derived COVID-19 vaccine candidate yesterday, administering the first doses in healthy human volunteers. Medicago is also planning a Phase 2/3 trial to be initiated this October. MEDICAGO ANNOUNCES POSITIVE RESULTS IN ANIMAL TRIALS FOR Quebec City, May 14, 2020 - Medicago, a biopharmaceutical company headquartered in Quebec City, announced today that its vaccine candidate for COVID-19 induced a positive antibody response only 10 days after a single dose in mice. “These positive results are pivotal to initiate a clinical study in healthy volunteers. Once results from a second ‘boost' dose are available, Medicago will VLP TECHNOLOGIES AND PRODUCTION PLATFORM Similar benefits, with potentially lower risks. Virus-like particles (VLPs) represent an exciting approach to vaccine development. VLPs mimic the native structure of viruses, allowing them to be easily recognized by the immune system. However, they lack core genetic material which makes them non-infectious and unable to replicate.MEDICAGO NEWSROOM
Transforming the approachto vaccines and therapeutic proteins. from Medicago's scientists and researchers. Prime-pull vaccination with a plant-derived virus-like particle influenza vaccine elicits a broad immune response and protects aged mice from death and frailty after challenge. Immunogenicity and safety of a quadrivalent plant-derived CONTACT US - MEDICAGO Medicago Inc. 1020 Route de l'Église. Suite 600. Quebec City, Quebec. G1V 3V9 Canada. Google Map. 1-418-658-9393 1-888-387-7848. MEDICAGO AND GSK ANNOUNCE POSITIVE INTERIM PHASE 2 RESULTS Medicago is a leading clinical-stage biopharmaceutical company using disruptive plant-based and virus-like particle (VLP) technologies to rapidly develop innovative vaccines and protein-based therapeutics for infectious diseases and emerging public health challenges. ACTUALITÉS DE MEDICAGO Voici les études et les articles publiés à ce jour par les chercheurs de Medicago. Voir plus. 13 octobre 2020 Vaccin. Lancet publication: First human efficacy study of a plant-derived influenza vaccine. Auteurs: Brian J Ward, Alexander Makarkov, Annie Séguin, Stéphane Pillet, Sonia Trépanier, Jiwanjeet Dhaliwall, Michael DLibman, Timo
MEDICAGO AWARDED %U201CBEST NEW VACCINE TECHNOLOGY Medicago Awarded “Best New Vaccine Technology/Platform” at the World Vaccine Congress. Washington, D.C., USA, April 25, 2019 – Medicago, a North American biotech company and global leader in the development and production of plant-derived vaccines, announced today that its proprietary plant-based production platform, Proficia® wasnamed
DEVELOPING NOVEL VACCINES AND THERAPEUTIC PROTEINS Medicago is a leading clinical-stage biopharmaceutical company using disruptive plant-based and virus-like particle (VLP) technologies to rapidly develop innovative vaccines and protein-based therapeutics for infectious diseases and emerging public health challenges. COVID-19 PROGRAMSNEWSROOMPIPELINE COVID-19 VaccineDevelopment Program. On March 12, 2020, Medicago announced the successful production of Virus-Like Particle (VLPs) of the coronavirus just 20 days after obtaining the SARS-CoV-2 (virus causing the COVID-19 disease) gene. Production of VLPs is the first step in developing a vaccine against COVID-19 before preclinicaltesting for
MEDICAGO AND GSK START PHASE 3 TRIAL OF ADJUVANTED COVID Medicago and GSK start Phase 3 trial of adjuvanted COVID-19 vaccine candidate. QUEBEC CITY, LONDON, March 16th, 2021 - Medicago, a biopharmaceutical company headquartered in Quebec City and GlaxoSmithKline (GSK), are pleased to announce the start of Phase 3 clinical testing of Medicago's plant-derived COVID-19 vaccine candidate in combinationABOUT MEDICAGO
Doing things differently since 1999. The story of Medicago is rooted in a long track record of innovation and perseverance. Even our company name – the Latin word for alfalfa, which was the first plant we worked with – embodies our culture of adaptation. We're proud of our humble beginnings as much as we are of our current growth andglobal
MEDIA ROOM - MEDICAGO Medicago is a leading clinical-stage biopharmaceutical company using disruptive plant-based and virus-like particle (VLP) technologies to rapidly develop innovative vaccines and protein-based therapeutics for infectious diseases and emerging public health challenges. DEVELOPING NOVEL VACCINES AND THERAPEUTIC PROTEINS Medicago is a leading clinical-stage biopharmaceutical company using disruptive plant-based and virus-like particle (VLP) technologies to rapidly develop innovative vaccines and protein-based therapeutics for infectious diseases and emerging public health challenges. COVID-19 PROGRAMSNEWSROOMPIPELINE COVID-19 VaccineDevelopment Program. On March 12, 2020, Medicago announced the successful production of Virus-Like Particle (VLPs) of the coronavirus just 20 days after obtaining the SARS-CoV-2 (virus causing the COVID-19 disease) gene. Production of VLPs is the first step in developing a vaccine against COVID-19 before preclinicaltesting for
MEDICAGO AND GSK START PHASE 3 TRIAL OF ADJUVANTED COVID Medicago and GSK start Phase 3 trial of adjuvanted COVID-19 vaccine candidate. QUEBEC CITY, LONDON, March 16th, 2021 - Medicago, a biopharmaceutical company headquartered in Quebec City and GlaxoSmithKline (GSK), are pleased to announce the start of Phase 3 clinical testing of Medicago's plant-derived COVID-19 vaccine candidate in combinationABOUT MEDICAGO
Doing things differently since 1999. The story of Medicago is rooted in a long track record of innovation and perseverance. Even our company name – the Latin word for alfalfa, which was the first plant we worked with – embodies our culture of adaptation. We're proud of our humble beginnings as much as we are of our current growth andglobal
MEDIA ROOM - MEDICAGO Medicago is a leading clinical-stage biopharmaceutical company using disruptive plant-based and virus-like particle (VLP) technologies to rapidly develop innovative vaccines and protein-based therapeutics for infectious diseases and emerging public health challenges. MEDICAGO ANNOUNCES POSITIVE PHASE 1 RESULTS FOR ITS COVID Medicago announces positive Phase 1 results for its COVID-19 vaccine candidate. 100 per cent of subjects who received an adjuvanted vaccine candidate developed significant antibody and cellular immune responses after two doses. QUEBEC CITY, November 10th, 2020 - Medicago, a biopharmaceutical company headquartered in Quebec City, is pleased to MEDICAGO BEGINS PHASE I CLINICAL TRIALS FOR ITS COVID-19 First doses administered to human volunteers. QUEBEC CITY, July 14, 2020 - Medicago, a biopharmaceutical company headquartered in Quebec City, began Phase I clinical trials for its plant-derived COVID-19 vaccine candidate yesterday, administering the first doses in healthy human volunteers. Medicago is also planning a Phase 2/3 trial to be initiated this October. VLP TECHNOLOGIES AND PRODUCTION PLATFORM Similar benefits, with potentially lower risks. Virus-like particles (VLPs) represent an exciting approach to vaccine development. VLPs mimic the native structure of viruses, allowing them to be easily recognized by the immune system. However, they lack core genetic material which makes them non-infectious and unable to replicate. MEDICAGO ANNOUNCES PRODUCTION OF A VIABLE VACCINE Medicago announces production of a viable vaccine candidate for COVID-19. March 12, 2020. Press Release. The biopharma successfully produced Virus-Like Particles (VLP) of the coronavirus in just 20 days using proprietary plant-based technology. Medicago's platform can produce both vaccine and antibody candidates against COVID-19 disease. PROGRAMMES COVID-19TRANSLATE THIS PAGE Medicago est une société biopharmaceutique de premier plan de stade clinique. À partir de technologies innovantes sur plantes, elle développe rapidement des vaccins novateursen particules pseudo-virales (PPV) et des traitements à base de protéines pour traiter les maladies infectieuses et les problèmes de santé publiqueémergents.
ACTUALITÉS DE MEDICAGO Voici les études et les articles publiés à ce jour par les chercheurs de Medicago. Voir plus. 13 octobre 2020 Vaccin. Lancet publication: First human efficacy study of a plant-derived influenza vaccine. Auteurs: Brian J Ward, Alexander Makarkov, Annie Séguin, Stéphane Pillet, Sonia Trépanier, Jiwanjeet Dhaliwall, Michael DLibman, Timo
MEDICAGO OFFICIALLY STARTS THE CONSTRUCTION OF ITS SITE IN Quebec City, September 18, 2018 - Medicago, a Canadian biotech company and global leader in the development and production of plant-based vaccines, is enthusiastically breaking ground for its commercial vaccine production facility today with the presence of Mr. Masayuki Mitsuka, President & CEO of Mitsubishi Tanabe Pharma Corporation and Mr. Regis Labeaume, Mayor of Quebec City and OPPORTUNITÉS D'EMPLOI À QUÉBEC Chez Medicago, c'est différent : nous comptons sur chaque employé pour participer directement au succès de l'entreprise. Dans le contexte de changement rapide et de forte croissance qu'est le nôtre, nous offrons aux employés plusieurs possibilités de progresser dans l'entreprise en acceptant de nouvelles responsabilités et de nouveauxMEDICAGO NEWSROOM
May 2, 2017 Human Vaccines & Immunotherapeutics. Plant-made virus-like particle vaccines bearing the hemagglutinin of either seasonal (H1) or avian (H5) influenza have distinct patterns of interaction with human immune cells in vitro. Authors: Hendin HE, Pillet S, Lara AN, Wu CY, Charland N, Landry N, Ward BJ. March 16, 2017 Vaccine. MEDICAGO ET GSK LANCENT LA PHASE III DE L'ESSAI …TRANSLATE THIS PAGE Medicago est une société biopharmaceutique de premier plan de stade clinique. À partir de technologies innovantes sur plantes, elle développe rapidement des vaccins novateursen particules pseudo-virales (PPV) et des traitements à base de protéines pour traiter les maladies infectieuses et les problèmes de santé publiqueémergents.
DEVELOPING NOVEL VACCINES AND THERAPEUTIC PROTEINS Medicago is a leading clinical-stage biopharmaceutical company using disruptive plant-based and virus-like particle (VLP) technologies to rapidly develop innovative vaccines and protein-based therapeutics for infectious diseases and emerging public health challenges. COVID-19 PROGRAMSNEWSROOMPIPELINE COVID-19 VaccineDevelopment Program. On March 12, 2020, Medicago announced the successful production of Virus-Like Particle (VLPs) of the coronavirus just 20 days after obtaining the SARS-CoV-2 (virus causing the COVID-19 disease) gene. Production of VLPs is the first step in developing a vaccine against COVID-19 before preclinicaltesting for
MEDICAGO AND GSK START PHASE 3 TRIAL OF ADJUVANTED COVID Medicago and GSK start Phase 3 trial of adjuvanted COVID-19 vaccine candidate. QUEBEC CITY, LONDON, March 16th, 2021 - Medicago, a biopharmaceutical company headquartered in Quebec City and GlaxoSmithKline (GSK), are pleased to announce the start of Phase 3 clinical testing of Medicago's plant-derived COVID-19 vaccine candidate in combinationABOUT MEDICAGO
Doing things differently since 1999. The story of Medicago is rooted in a long track record of innovation and perseverance. Even our company name – the Latin word for alfalfa, which was the first plant we worked with – embodies our culture of adaptation. We're proud of our humble beginnings as much as we are of our current growth andglobal
HEALTH CANADA INITIATES THE REVIEW OF THE ROLLING QUEBEC CITY, April 23rd, 2021 - Medicago, a biopharmaceutical company headquartered in Quebec City is pleased to announce that Health Canada received for review the first portion of Medicago’s plant-derived adjuvanted COVID-19 vaccine candidate rolling submission on April 19, 2021. The Interim Order (IO) rolling submission allows Medicago to submit nonclinical sections, quality and MISE AU POINT DE NOUVEAUX VACCINS ET PROTÉINES Medicago est une société biopharmaceutique de premier plan de stade clinique. À partir de technologies innovantes sur plantes, elle développe rapidement des vaccins novateursen particules pseudo-virales (PPV) et des traitements à base de protéines pour traiter les maladies infectieuses et les problèmes de santé publiqueémergents.
DEVELOPING NOVEL VACCINES AND THERAPEUTIC PROTEINS Medicago is a leading clinical-stage biopharmaceutical company using disruptive plant-based and virus-like particle (VLP) technologies to rapidly develop innovative vaccines and protein-based therapeutics for infectious diseases and emerging public health challenges. COVID-19 PROGRAMSNEWSROOMPIPELINE COVID-19 VaccineDevelopment Program. On March 12, 2020, Medicago announced the successful production of Virus-Like Particle (VLPs) of the coronavirus just 20 days after obtaining the SARS-CoV-2 (virus causing the COVID-19 disease) gene. Production of VLPs is the first step in developing a vaccine against COVID-19 before preclinicaltesting for
MEDICAGO AND GSK START PHASE 3 TRIAL OF ADJUVANTED COVID Medicago and GSK start Phase 3 trial of adjuvanted COVID-19 vaccine candidate. QUEBEC CITY, LONDON, March 16th, 2021 - Medicago, a biopharmaceutical company headquartered in Quebec City and GlaxoSmithKline (GSK), are pleased to announce the start of Phase 3 clinical testing of Medicago's plant-derived COVID-19 vaccine candidate in combinationABOUT MEDICAGO
Doing things differently since 1999. The story of Medicago is rooted in a long track record of innovation and perseverance. Even our company name – the Latin word for alfalfa, which was the first plant we worked with – embodies our culture of adaptation. We're proud of our humble beginnings as much as we are of our current growth andglobal
HEALTH CANADA INITIATES THE REVIEW OF THE ROLLING QUEBEC CITY, April 23rd, 2021 - Medicago, a biopharmaceutical company headquartered in Quebec City is pleased to announce that Health Canada received for review the first portion of Medicago’s plant-derived adjuvanted COVID-19 vaccine candidate rolling submission on April 19, 2021. The Interim Order (IO) rolling submission allows Medicago to submit nonclinical sections, quality and MISE AU POINT DE NOUVEAUX VACCINS ET PROTÉINES Medicago est une société biopharmaceutique de premier plan de stade clinique. À partir de technologies innovantes sur plantes, elle développe rapidement des vaccins novateursen particules pseudo-virales (PPV) et des traitements à base de protéines pour traiter les maladies infectieuses et les problèmes de santé publiqueémergents.
MEDICAGO ANNOUNCES POSITIVE PHASE 1 RESULTS FOR ITS COVID Medicago announces positive Phase 1 results for its COVID-19 vaccine candidate. 100 per cent of subjects who received an adjuvanted vaccine candidate developed significant antibody and cellular immune responses after two doses. QUEBEC CITY, November 10th, 2020 - Medicago, a biopharmaceutical company headquartered in Quebec City, is pleased to MEDICAGO BEGINS PHASE I CLINICAL TRIALS FOR ITS COVID-19 First doses administered to human volunteers. QUEBEC CITY, July 14, 2020 - Medicago, a biopharmaceutical company headquartered in Quebec City, began Phase I clinical trials for its plant-derived COVID-19 vaccine candidate yesterday, administering the first doses in healthy human volunteers. Medicago is also planning a Phase 2/3 trial to be initiated this October. MEDICAGO ANNOUNCES PRODUCTION OF A VIABLE VACCINE Medicago announces production of a viable vaccine candidate for COVID-19. March 12, 2020. Press Release. The biopharma successfully produced Virus-Like Particles (VLP) of the coronavirus in just 20 days using proprietary plant-based technology. Medicago's platform can produce both vaccine and antibody candidates against COVID-19 disease. VLP TECHNOLOGIES AND PRODUCTION PLATFORM Similar benefits, with potentially lower risks. Virus-like particles (VLPs) represent an exciting approach to vaccine development. VLPs mimic the native structure of viruses, allowing them to be easily recognized by the immune system. However, they lack core genetic material which makes them non-infectious and unable to replicate. PROGRAMMES COVID-19TRANSLATE THIS PAGE Medicago est une société biopharmaceutique de premier plan de stade clinique. À partir de technologies innovantes sur plantes, elle développe rapidement des vaccins novateursen particules pseudo-virales (PPV) et des traitements à base de protéines pour traiter les maladies infectieuses et les problèmes de santé publiqueémergents.
MEDICAGO OFFICIALLY STARTS THE CONSTRUCTION OF ITS SITE IN Quebec City, September 18, 2018 - Medicago, a Canadian biotech company and global leader in the development and production of plant-based vaccines, is enthusiastically breaking ground for its commercial vaccine production facility today with the presence of Mr. Masayuki Mitsuka, President & CEO of Mitsubishi Tanabe Pharma Corporation and Mr. Regis Labeaume, Mayor of Quebec City and ACTUALITÉS DE MEDICAGO Voici les études et les articles publiés à ce jour par les chercheurs de Medicago. Voir plus. 13 octobre 2020 Vaccin. Lancet publication: First human efficacy study of a plant-derived influenza vaccine. Auteurs: Brian J Ward, Alexander Makarkov, Annie Séguin, Stéphane Pillet, Sonia Trépanier, Jiwanjeet Dhaliwall, Michael DLibman, Timo
MEDICAGO NEWSROOM
May 2, 2017 Human Vaccines & Immunotherapeutics. Plant-made virus-like particle vaccines bearing the hemagglutinin of either seasonal (H1) or avian (H5) influenza have distinct patterns of interaction with human immune cells in vitro. Authors: Hendin HE, Pillet S, Lara AN, Wu CY, Charland N, Landry N, Ward BJ. March 16, 2017 Vaccine. OPPORTUNITÉS D'EMPLOI À QUÉBEC Chez Medicago, c'est différent : nous comptons sur chaque employé pour participer directement au succès de l'entreprise. Dans le contexte de changement rapide et de forte croissance qu'est le nôtre, nous offrons aux employés plusieurs possibilités de progresser dans l'entreprise en acceptant de nouvelles responsabilités et de nouveaux MEDICAGO ET GSK LANCENT LA PHASE III DE L'ESSAI …TRANSLATE THIS PAGE Medicago est une société biopharmaceutique de premier plan de stade clinique. À partir de technologies innovantes sur plantes, elle développe rapidement des vaccins novateursen particules pseudo-virales (PPV) et des traitements à base de protéines pour traiter les maladies infectieuses et les problèmes de santé publiqueémergents.
Aller au contenu
* Programmes COVID-19* Entreprise
* Technologies
* Découvertes
* Portefeuille
* Actualités
* Carrières
* Contact
* EN
L'AVENIR SE CULTIVE ICI V o i r l a V i d é oDéfiler
COVID-19
Programmes de recherche Médicago bénéficie d'une dérogation du Gouvernement du Québec afin de poursuivre la construction de son usine de production devaccins à Québec.
En savoir plus
NOS TECHNOLOGIES NOVATRICES LES TECHNOLOGIES DE MEDICAGO RÉVOLUTIONNENT LE DÉVELOPPEMENT DE VACCINS ET DE PROTÉINES THÉRAPEUTIQUES ET LA LUTTE CONTRE LESPANDÉMIES .
Particules pseudo-virales Reproduisant la structure d'un virus mais sans son matériel génétique, ces particules stimulent grandement la production d'anticorps et la réponse immunitaire à médiation cellulaire.En savoir plus
Production sur plante Notre plateforme de production offre des avantages indéniables pour la lutte contre les maladies et les pandémies : fidélité, rapidité, ampleur modulable et polyvalence.En savoir plus
Plateformes de découverte Notre plateforme de criblage rapide à haut débit accélère la découverte et le développement de nouvelles protéinesrecombinantes.
En savoir plus
NOS
PROJETS EN COURS
Modulable et polyvalente, notre plateforme de découverte et de développement éprouvée permet la création d’une filière de produits robuste et prometteuse.INFLUENZA
En savoir plus
NOROVIRUS
En savoir plus
CORONAVIRUS
En savoir plus
ROTAVIRUS
En savoir plus
PROGRAMMES DE DÉCOUVERTEEn savoir plus
NOTRE VISION
UN MONDE PRÊT À COMBATTRE N'IMPORTE QUELLE MALADIE. Medicago s'emploie à concevoir et à appliquer des solutions aux problèmes de santé mondiaux. Depuis le début, nous croyons fermement qu'on peut réussir mieux en faisant les choses différemment, par l'innovation constante et des recherchesrigoureuses.
Grâce à notre plateforme de développement et de fabrication rapides, nous pouvons participer activement aux efforts de préparation et de lutte contre les menaces de pandémie et autres maladies émergentes. En savoir plus sur notre parcoursVOYEZ LOIN,
VOYEZ GRAND
CHEZ MEDICAGO, CHAQUE EMPLOYÉ EST IMPORTANT. Que vous soyez un technicien débutant ou un cadre chevronné : vous pouvez contribuer activement au succès de notre entreprise. Avec la commercialisation imminente de notre premier produit et notre filière prometteuse, nous comptons sur chaque employé pour concrétiser ses idées et mettre à profit son dynamisme. Si vous cherchez un employeur qui valorise l’implication et l’innovation dans un contexte de collaboration et de forte croissance, Medicago est le milieu de travail parfait.Offres d'emploi
* Entreprise
* Notre parcours
* Nos Dirigeants
* Nos Établissements* Notre Réseau
* Programmes
COVID-19
* Technologies
* Particules Pseudo-Virales * Plateforme de production* Découvertes
* Plateformes de Découvertes * Découvertes de Vaccins * Découverte d'Anticorps * Nouvelles applications* Portefeuille
* Vue d'ensemble
* Influenza
* Rotavirus
* Norovirus
* Actualités
* En Manchettes
* Publications
Scientifiques
* Carrières
* Emploi
* Nos gens
* Nos Valeurs
* Équipes
* Recherche d'emploi INFOLETTRE ABONNEZ-VOUS !* Youtube
* Contact
* Légal
* Confidentialité
Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0